PolyPid (NASDAQ:PYPD) Stock Price Up 3.3% - Still a Buy?

Key Points

• Shares jumped 3.3% to $4.37 on Thursday but on light volume (13,903 shares, about 75% below the average); the stock sits near its 50‑day ($4.35) and 200‑day ($4.04) moving averages.
• Analysts are mixed but leaning positive with a MarketBeat consensus of "Moderate Buy" and an average price target of $12.25 (five Buy ratings vs. one Sell, including a $13 target from HC Wainwright and a D‑ sell from Weiss).
• PolyPid is a clinical‑stage biotech (market cap ~$83.4M) with negative earnings—quarterly EPS of -$0.41 missed estimates and analysts project -1.79 EPS for the fiscal year—developing mucosal drug‑delivery candidates like OncoTears, OralTear and Paclical.

PolyPid Ltd. (NASDAQ:PYPD - Get Free Report)'s share price shot up 3.3% on Thursday . The company traded as high as $4.37 and last traded at $4.37. 13,903 shares were traded during trading, a decline of 75% from the average session volume of 56,428 shares. The stock had previously closed at $4.23.

Wall Street Analyst Weigh In

A number of research firms have issued reports on PYPD. Weiss Ratings restated a "sell (d-)" rating on shares of PolyPid in a report on Monday, December 29th. Wall Street Zen upgraded PolyPid from a "sell" rating to a "hold" rating in a research note on Saturday, March 14th. Finally, HC Wainwright restated a "buy" rating and set a $13.00 target price on shares of PolyPid in a research note on Wednesday, February 11th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $12.25.

PolyPid Stock Up 3.3%

The firm has a market cap of $83.38 million, a P/E ratio of -1.93 and a beta of 1.45. The stock's 50-day moving average is $4.35 and its 200-day moving average is $4.04.

PolyPid (NASDAQ:PYPD - Get Free Report) last issued its quarterly earnings results on Wednesday, February 11th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.07). As a group, analysts expect that PolyPid Ltd. will post -1.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of PYPD. XTX Topco Ltd boosted its stake in PolyPid by 50.0% during the fourth quarter. XTX Topco Ltd now owns 32,661 shares of the company's stock worth $142,000 after buying an additional 10,888 shares in the last quarter. ADAR1 Capital Management LLC acquired a new position in shares of PolyPid in the 4th quarter valued at $451,000. Jane Street Group LLC acquired a new position in shares of PolyPid in the 4th quarter valued at $66,000. HighTower Advisors LLC bought a new position in shares of PolyPid during the 4th quarter worth about $44,000. Finally, AIGH Capital Management LLC lifted its holdings in shares of PolyPid by 26.1% during the 4th quarter. AIGH Capital Management LLC now owns 1,342,972 shares of the company's stock worth $5,828,000 after acquiring an additional 277,844 shares during the period. 26.47% of the stock is currently owned by institutional investors and hedge funds.

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.